Tenaya Therapeutics, Inc.

Tenaya Therapeutics is a clinical-stage biotechnology company focused on discovering, developing, and delivering potentially curative therapies that address the underlying genetic drivers of heart disease. The company trades on the Nasdaq Global Select Stock Market under a ticker symbol to be specified in the complete filing. More information about the company is available at its website.

The company's pipeline consists of three clinical-stage programs and multiple early-stage candidates across various therapeutic modalities. TN-201 is an AAV9-based gene therapy in Phase 1b/2 development for MYBPC3-associated hypertrophic cardiomyopathy, a condition affecting approximately 120,000 patients in the United States. MYBPC3 mutations represent the most common genetic cause of HCM, and TN-201 is designed to deliver a functional MYBPC3 gene to heart muscle cells via a single intravenous infusion. TN-401, also in Phase 1b/2 testing, targets PKP2-associated arrhythmogenic right ventricular cardiomyopathy, which affects more than 70,000 patients in the United States. TN-301 is a small molecule HDAC6 inhibitor that completed Phase 1 clinical testing and is being evaluated for heart failure with preserved ejection fraction and other cardiac and metabolic conditions.

Tenaya's competitive advantages stem from its integrated platform capabilities, which include human-induced pluripotent stem cell-derived disease models, machine learning-enabled phenotypic screening, AAV capsid engineering, and proprietary promoter constructs. The company has internalized expertise in manufacturing and process development for gene therapy candidates, supporting its ability to produce clinical trial materials and manage late-stage manufacturing requirements.

In March 2026, Tenaya entered into a multi-target research collaboration with Alnylam Pharmaceuticals to identify and validate novel gene targets for cardiovascular disease treatment. Under this agreement, Tenaya is eligible to receive up to $1.13 billion in development, regulatory, and sales-based milestones related to products directed to targets the company nominates.

The company's strategy emphasizes developing disease-modifying therapies targeting defined patient subpopulations with well-established genetic causes of disease. For rare disease programs, Tenaya intends to develop, manufacture, and commercialize products independently, while pursuing partnerships for programs addressing more prevalent indications.